Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Interest Expenses (2021 - 2022)

CNBX Pharmaceuticals (CNBX) has disclosed Interest Expenses for 7 consecutive years, with $14154.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Interest Expenses fell 83.31% year-over-year to $14154.0, compared with a TTM value of $14154.0 through May 2023, down 89.23%, and an annual FY2025 reading of $42285.0, up 82.86% over the prior year.
  • Interest Expenses was $14154.0 for Q3 2022 at CNBX Pharmaceuticals, down from $46646.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $647523.0 in Q2 2021 and bottomed at $14154.0 in Q3 2022.